Stephan Schwers

Wuppertal, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Clinical laboratory diagnostics and monitoring of ADAMTS13 deficiency and of related diseases: an integrated approach.

Clinical laboratory diagnostics and monitoring of ADAMTS13 deficiency and of related diseases: an integrated approach.

Journal: Expert review of hematology

Published: July 16, 2026

Review of laboratory methods used for analysis of von Willebrand factor and for diagnosis of related diseases.

Review of laboratory methods used for analysis of von Willebrand factor and for diagnosis of related diseases.

Journal: Expert review of hematology

Published: July 04, 2025

Von Willebrand factor is a multifaceted player in hemostasis requiring a diverse array of analytical and diagnostic approaches.

Von Willebrand factor is a multifaceted player in hemostasis requiring a diverse array of analytical and diagnostic approaches.

Journal: Expert review of hematology

Published: June 24, 2025

Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers.

Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers.

Journal: Clinical and translational science

Published: January 10, 2024

Longitudinal observations of TFPI levels in paediatric Haemophilia A patients.

Longitudinal observations of TFPI levels in paediatric Haemophilia A patients.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: April 04, 2023

The effect of rivaroxaban on biomarkers in blood and plasma: a review of preclinical and clinical evidence.

The effect of rivaroxaban on biomarkers in blood and plasma: a review of preclinical and clinical evidence.

Journal: Journal of thrombosis and thrombolysis

Published: January 15, 2023

Predictive value for increased activated factor XI activity in acute venous thromboembolism.

Predictive value for increased activated factor XI activity in acute venous thromboembolism.

Journal: Journal of thrombosis and haemostasis : JTH

Published: October 11, 2022

Subtype-specific plasma signatures of platelet-related protein releasate in acute pulmonary embolism.

Subtype-specific plasma signatures of platelet-related protein releasate in acute pulmonary embolism.

Journal: Thrombosis research

Published: August 10, 2022

First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men.

First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men.

Journal: Journal of thrombosis and haemostasis : JTH

Published: December 08, 2021

Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple-dose study.

Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple-dose study.

Journal: British journal of clinical pharmacology

Published: September 22, 2021

Association of FXI activity with thrombo-inflammation, extracellular matrix, lipid metabolism and apoptosis in venous thrombosis.

Association of FXI activity with thrombo-inflammation, extracellular matrix, lipid metabolism and apoptosis in venous thrombosis.

Journal: Scientific reports

Published: July 28, 2021

Clinical use of thrombin generation assays.

Clinical use of thrombin generation assays.

Journal: Journal of thrombosis and haemostasis : JTH

Published: April 02, 2021

Showing 1-12 of 21

Last Updated: 09/26/2026